Benucci Maurizio, Saviola Gianantonio, Manfredi Mariangela, Sarzi-Puttini Piercarlo, Atzeni Fabiola
Rheumatology Unit, Department of Internal Medicine, Hospital di S. Giovanni di Dio, Azienda Sanitaria di Firenze, Italy.
Acta Biomed. 2012 Apr;83(1):72-80.
Five anti-TNF agents, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol are approved worldwide for the treatment of RA. Anti-TNF agents, bind to and neutralize soluble TNF-alpha, but exert different effects on transmembrane TNF-alpha-expressing cells (TNF-alpha-producing cells). Differences on affinity and avidity for soluble and transmembrane TNF-alpha were showed. Different activity on cells apoptosis, complement-dependent cytotoxicity (CDC) antibody dependent cell-mediated cytotoxicity (ACDC) were described. Some dramatic changes in gene expression were seen with all the anti-TNFs. Reviewing the biology of transmembrane TNF-alpha and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.
五种抗 TNF 药物，英夫利昔单抗、阿达木单抗、依那西普、戈利木单抗和聚乙二醇化赛妥珠单抗在全球范围内被批准用于治疗类风湿性关节炎（RA）。抗 TNF 药物与可溶性 TNF-α 结合并中和，但对表达跨膜 TNF-α 的细胞（产生 TNF-α 的细胞）产生不同的作用。研究表明它们对可溶性和跨膜 TNF-α 的亲和力和avidity存在差异。还描述了它们在细胞凋亡、补体依赖性细胞毒性（CDC）及抗体依赖性细胞介导的细胞毒性（ACDC）方面的不同活性。使用所有抗 TNF 药物均可见基因表达的一些显著变化。回顾跨膜 TNF-α 的生物学特性及其与抗 TNF 药物的相互作用，将有助于理解这些有前景的治疗方式产生不同临床疗效的基础。
